IPHA logo

IPHA
Innate Pharma

1,486
Mkt Cap
$134.14M
Volume
4,539.00
52W High
$2.63
52W Low
$1.17
PE Ratio
-2.33
IPHA Fundamentals
Price
$1.37
Prev Close
$1.43
Open
$1.44
50D MA
$1.52
Beta
0.54
Avg. Volume
21,694.41
EPS (Annual)
-$0.6195
P/B
-5.26
Rev/Employee
$19,296.61
$143.00
Loading...
Loading...
News
all
press releases
Innate Pharma to Participate in the D. Boral Capital Global Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in one-on-one investor meetings at the following...
Business Wire·17h ago
News Placeholder
More News
News Placeholder
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), today announced that interim results from the MATISSE Phase 2 study evaluating IPH5201 in combination...
Business Wire·6d ago
News Placeholder
Innate Pharma (OTCMKTS:IPHYF) Stock Price Up 9.3% - Here's What Happened
Innate Pharma (OTCMKTS:IPHYF) Stock Price Up 9.3% - Time to Buy...
MarketBeat·9d ago
News Placeholder
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
Regulatory News: Pursuant to the article L. 233-8 II of the French Code de Commerce and the article 223-16 of the French stock-market authorities (Autorit des Marchs Financiers, or AMF) General...
Business Wire·11d ago
News Placeholder
HC Wainwright Decreases Earnings Estimates for Innate Pharma
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Free Report) - Stock analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for shares of Innate Pharma in a report released on Tuesday, April 7th. HC Wainwright analyst S. Ramakanth now anticipates that the company will po...
MarketBeat·13d ago
News Placeholder
Brokers Set Expectations for Innate Pharma FY2030 Earnings
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA - Free Report) - Equities researchers at HC Wainwright issued their FY2030 EPS estimates for Innate Pharma in a research report issued on Tuesday, April...
MarketBeat·14d ago
News Placeholder
Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ('Innate' or the 'Company'), announced today that Yannis Morel, Chief Operating Officer, will present at the AACR Oncology...
Business Wire·16d ago
News Placeholder
Innate Pharma (NASDAQ:IPHA) Given "Buy" Rating at HC Wainwright
HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Innate Pharma in a research note on Tuesday...
MarketBeat·16d ago
News Placeholder
Innate Pharma to Participate in the Kempen Life Sciences Conference
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced...
Business Wire·21d ago
News Placeholder
Innate Pharma Files Its 2025 Universal Registration Document (Document Denregistrement Universel) and 2025 Form 20-f Annual Report
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (Innate or the Company) today announced the filing of its 2025 Universal Registration Document (Document denregistrement...
Business Wire·22d ago
<
1
2
...
>

Latest IPHA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.